0001209191-23-047756.txt : 20230830 0001209191-23-047756.hdr.sgml : 20230830 20230830172215 ACCESSION NUMBER: 0001209191-23-047756 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230828 FILED AS OF DATE: 20230830 DATE AS OF CHANGE: 20230830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Johnston John Joseph CENTRAL INDEX KEY: 0001874850 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 231226165 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-28 0 0001287098 MAXCYTE, INC. MXCT 0001874850 Johnston John Joseph C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 1 0 0 0 1 Common Stock 2023-08-28 4 M 0 100 1.641 A 120683 D Common Stock 2023-08-28 4 S 0 100 3.70 D 120583 D Common Stock 2023-08-29 4 M 0 2059 1.641 A 122642 D Common Stock 2023-08-29 4 S 0 2059 3.70 D 120583 D Common Stock 2023-08-30 4 M 0 2841 1.641 A 123424 D Common Stock 2023-08-30 4 S 0 2841 3.70 D 120583 D Stock Option (right to buy) 1.641 2023-08-28 4 M 0 100 0.00 D 2030-01-20 Common Stock 100 13617 D Stock Option (right to buy) 1.641 2023-08-29 4 M 0 2059 0.00 D 2030-01-20 Common Stock 2059 11558 D Stock Option (right to buy) 1.641 2023-08-30 4 M 0 2841 0.00 D 2030-01-20 Common Stock 2841 8717 D The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. /s/ Katie Kazem, Attorney-in-Fact 2023-08-30